In summary, we investigated the migratory capacity of T cell subsets in alemtuzumab-treated and treatment naïve RRMS patients and found that in alemtuzumab-treated patients, CD4+ TEM cells and CD8+ TCM cells had defective migration in our BBB model. Here, CD8A is linked to relapsing-remitting multiple sclerosis.